PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Linda Vidarsdottir, Alireza Azimi, Ishani Das, Ingibjorg Sigvaldadottir, Aldwin Suryo Rahmanto, Andreas Petri, Sakari Kauppinen, Christian Ingvar, Göran Jönsson, Håkan Olsson, Marianne Frostvik Stolt, Rainer Tuominen, Olle Sangfelt, Katja Pokrovskaja Tamm, Johan Hansson, Dan Grandér, Suzanne Egyházi Brage*, Per Johnsson*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

2 Downloads (Pure)
Original languageEnglish
Article number11023
JournalScientific Reports
Volume11
Issue number1
Number of pages11
ISSN2045-2322
DOIs
Publication statusPublished - 26 May 2021

Fingerprint

Dive into the research topics of 'PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma'. Together they form a unique fingerprint.

Cite this